OncoMatch/Clinical Trials/NCT06255210

Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)

Is NCT06255210 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP) for olfactory neuroblastoma.

Phase 2RecruitingHongmeng YuNCT06255210Data as of May 2026

Treatment: Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP) — The goal of this clinical trial is to learn about the induction chemotherapy efficacy in olfactory neuroblastoma. The main question it aims to answer is: wether olfactory neuroblastoma patients with different pathology subtypes apply to different induction chemotherapy schemes. Participants will be treated with different chemotherapy schemes, to evaluate the tumor remission rate and long term survival.

Check if I qualify

Extracted eligibility criteria

Cancer type

Neuroblastoma

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify